SCHEMBL15467136

SCHEMBL15467136

O=C(N[C@]1(c2ccc(Cl)c(Cl)c2)CCOc2cccnc21)c1ccccc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TRPM8 Q7Z2W7 1/20 0.50
RAB9A P51151 8/20 0.39
NPC1 O15118 7/20 0.39
SMN1; SMN2 Q16637 3/20 0.39
HDAC1 Q13547 2/20 0.38
HDAC3 O15379 1/20 0.36
HDAC2 Q92769 1/20 0.36
HDAC6 Q9UBN7 1/20 0.36
MAPT P10636 1/20 0.36
THRB P10828 1/20 0.36
ACVRL1 P37023 1/20 0.36
ROCK2 O75116 1/20 0.35
TRPV3 Q8NET8 1/20 0.35
P2RX7 Q99572 1/20 0.35
GRM4 Q14833 1/20 0.35
PKM P14618 1/20 0.34
MAOB P27338 1/20 0.34
MEN1 O00255 1/20 0.34
POLB P06746 1/20 0.34
KMT2A Q03164 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15467138 1.00 TRPM8 (0.50) TRPM8RAB9ANPC1SMN1; SMN2HDAC1
SCHEMBL15467950 0.91 TRPM8 (0.50) TRPM8RAB9ANPC1SMN1; SMN2MAPT
SCHEMBL15467951 0.91 TRPM8 (0.50) TRPM8RAB9ANPC1SMN1; SMN2MAPT
SCHEMBL15467575 0.91 TRPM8 (0.52) TRPM8RAB9ANPC1SMN1; SMN2HDAC1
SCHEMBL15467016 0.89 TRPM8 (0.52) TRPM8RAB9ANPC1SMN1; SMN2PKM
SCHEMBL15467015 0.89 TRPM8 (0.52) TRPM8RAB9ANPC1SMN1; SMN2PKM
SCHEMBL15467040 0.87 TRPM8 (0.54) TRPM8RAB9ANPC1SMN1; SMN2HDAC1
SCHEMBL15467332 0.87 TRPM8 (0.46) TRPM8RAB9ANPC1SMN1; SMN2HDAC1
SCHEMBL15467330 0.87 TRPM8 (0.46) TRPM8RAB9ANPC1SMN1; SMN2HDAC1
SCHEMBL15467734 0.86 TRPM8 (0.51) TRPM8RAB9ANPC1SMN1; SMN2HDAC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8952009-B2 Chroman derivatives as TRPM8 inhibitors AMGEN INC. (US) 2015-02-10 US claimed
US-20140045855-A1 CHROMAN DERIVATIVES AS TRPM8 INHIBITORS AMGEN INC. (US) 2014-02-13 US claimed
WO-2014025651-A1 CHROMAN DERIVATIVES AS TRPM8 INHIBITORS AMGEN INC. (US) 2014-02-13 WO claimed
US-8952009-B2 Chroman derivatives as TRPM8 inhibitors AMGEN INC. (US) 2015-02-10 US disclosed
US-8952009-B2 Chroman derivatives as TRPM8 inhibitors AMGEN INC. (US) 2015-02-10 US disclosed
US-8952009-B2 Chroman derivatives as TRPM8 inhibitors AMGEN INC. (US) 2015-02-10 US disclosed
US-20150031668-A1 CHROMAN DERIVATIVES AS TRPM8 INHIBITORS AMGEN INC (US) 2015-01-29 US disclosed
US-20150031668-A1 CHROMAN DERIVATIVES AS TRPM8 INHIBITORS AMGEN INC (US) 2015-01-29 US disclosed
US-20150031668-A1 CHROMAN DERIVATIVES AS TRPM8 INHIBITORS AMGEN INC (US) 2015-01-29 US disclosed
US-20140045855-A1 CHROMAN DERIVATIVES AS TRPM8 INHIBITORS AMGEN INC. (US) 2014-02-13 US disclosed
US-20140045855-A1 CHROMAN DERIVATIVES AS TRPM8 INHIBITORS AMGEN INC. (US) 2014-02-13 US disclosed
WO-2014025651-A1 CHROMAN DERIVATIVES AS TRPM8 INHIBITORS AMGEN INC. (US) 2014-02-13 WO disclosed
US-20140045855-A1 CHROMAN DERIVATIVES AS TRPM8 INHIBITORS AMGEN INC. (US) 2014-02-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150031668-A1 CHROMAN DERIVATIVES AS TRPM8 INHIBITORS TRPM8, TRPM5, TRPM7 TRPM8 1/4885RAB9A 1056/4885NPC1 702/4885
US-20140045855-A1 CHROMAN DERIVATIVES AS TRPM8 INHIBITORS TRPM8, TRPM5, TRPM7 TRPM8 1/4885RAB9A 1056/4885NPC1 702/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.